Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.34 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31105888 | 1.00 | FABP3 (0.51) | FABP3MRGPRX4CYP3A4MAPK1TSHR | |
| SCHEMBL121772 | 0.84 | FABP3 (0.49) | FABP3MRGPRX4CYP3A4MAPK1TSHR | |
| SCHEMBL30552290 | 0.84 | FABP3 (0.49) | FABP3MRGPRX4CYP3A4MAPK1TSHR | |
| SCHEMBL2929232 | 0.84 | FABP3 (0.49) | FABP3MRGPRX4CYP3A4MAPK1TSHR | |
| SCHEMBL5460219 | 0.83 | FABP3 (0.49) | FABP3MRGPRX4CYP3A4MAPK1TSHR | |
| SCHEMBL1590567 | 0.83 | DPP4 (0.41) | FABP3MRGPRX4CYP3A4MAPK1TSHR | |
| SCHEMBL2849811 | 0.83 | FABP3 (0.47) | FABP3MRGPRX4CYP3A4MAPK1TSHR | |
| SCHEMBL5790540 | 0.81 | FABP3 (0.46) | FABP3MRGPRX4CYP3A4MAPK1TSHR | |
| SCHEMBL8860109 | 0.81 | KDM4E (0.50) | FABP3MRGPRX4CYP3A4MAPK1TSHR | |
| SCHEMBL100191 | 0.81 | TSHR (0.50) | FABP3MRGPRX4CYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 784 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103068853-B | Synergistic biomolecule-polymer conjugates | PEG生物制药公司 | 2016-08-10 | — | — | CN | claimed |
| US-9364553-B2 | Synergistic biomolecule-polymer conjugates | PEG BIOSCIENCES, INC. (US) | 2016-06-14 | — | — | US | claimed |
| US-20160017058-A1 | BISPECIFIC ANTIBODIES AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-21 | — | — | US | claimed |
| EP-2970505-A1 | BISPECIFIC ANTIBODIES AND USES THEREOF | The California Institute for Biomedical Research (US) | 2016-01-20 | — | — | EP | claimed |
| US-20140335051-A1 | SYNERGISTIC BIOMOLECULE-POLYMER CONJUGATES | PEG BIOSCIENCES, INC. (US) | 2014-11-13 | — | — | US | claimed |
| WO-2014153002-A1 | BISPECIFIC ANTIBODIES AND USES THEREOF | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-09-25 | — | — | WO | claimed |
| US-20130195799-A1 | SYNERGISTIC BIOMOLECULE-POLYMER CONJUGATES | PEG BIOSCIENCES, INC. (US) | 2013-08-01 | — | — | US | claimed |
| EP-2606072-A1 | SYNERGISTIC BIOMOLECULE-POLYMER CONJUGATES | PEG Biosciences, Inc. (US) | 2013-06-26 | — | — | EP | claimed |
| US-8354477-B2 | Multi-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules | NEKTAR THERAPEUTICS (US) | 2013-01-15 | — | — | US | claimed |
| WO-2012024613-A1 | SYNERGISTIC BIOMOLECULE-POLYMER CONJUGATES | WINTRANCE CORPORATION (US) | 2012-02-23 | — | — | WO | claimed |
| EP-1479401-A2 | Drug release stent coating and process | Boston Scientific Scimed, Inc. (US) | 2004-11-24 | — | — | EP | claimed |
| US-20030114647-A1 | Multi-armed, monofunctional, and hydrolytically stable derivatives of poly (ethylene glycol) and related polymers for modification of surfaces and molecules | SHEARWATER CORPORATION | 2003-06-19 | — | — | US | claimed |
| CN-1353626-A | Composite membrane with polyalkylene oxide modified polyamide surface | DOW CHEMICAL CO (US) | 2002-06-12 | — | — | CN | claimed |
| EP-1200178-A1 | COMPOSITE MEMBRANE WITH POLYALKYLENE OXIDE MODIFIED POLYAMIDE SURFACE | THE DOW CHEMICAL COMPANY (US) | 2002-05-02 | — | — | EP | claimed |
| US-6280853-B1 | CROSSLINKED POLYAMIDES ON SUPPORTS WITH GRAFTING POLYOXYALKYLENE OXIDE GROUPS | THE DOW CHEMICAL COMPANY | 2001-08-28 | — | — | US | claimed |
| US-20010007765-A1 | MULTI-ARMED, MONOFUNCTIONAL, AND HYDROLYTICALLY STABLE DERIVATIVES OF POLY (ETHYLENE GLYCOL) AND RELATED POLYMERS FOR MODIFICATION OF SURFACES AND MOLECULES | NEKTAR THERAPEUTICS | 2001-07-12 | — | — | US | claimed |
| WO-2000076641-A1 | COMPOSITE MEMBRANE WITH POLYALKYLENE OXIDE MODIFIED POLYAMIDE SURFACE | THE DOW CHEMICAL COMPANY (US) | 2000-12-21 | — | — | WO | claimed |
| US-5932462-A | PURE WATER SOLUBLE POLYMER LINKED TO SINGLE IONIZABLE REACTIVE GROUP BY NONREACTIVE LINKAGE FRAGMENTS WITH NO AROMATIC RINGS AND ESTER GROUPS; CAN BE PURIFIED BY ION EXCHANGE CHROMATOGRAPHY | SHEARWATER POLYMERS, INC. (US) | 1999-08-03 | — | — | US | claimed |
| EP-0832655-A2 | Drug release stent coating and process | SCHNEIDER (USA) INC. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996021469-A1 | MULTI-ARMED, MONOFUNCTIONAL, AND HYDROLYTICALLY STABLE DERIVATIVES OF POLY(ETHYLENE GLYCOL) AND RELATED POLYMERS FOR MODIFICATION OF SURFACES AND MOLECULES | SHEARWATER POLYMERS, INC. (US) | 1996-07-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335051-A1 | SYNERGISTIC BIOMOLECULE-POLYMER CONJUGATES | CD44, VEGFA, HDGF | FABP3 156/4885MRGPRX4 1187/4885CYP3A4 2117/4885 |
| US-20160017058-A1 | BISPECIFIC ANTIBODIES AND USES THEREOF | FCGR3B, CD22, CD14 | FABP3 1480/4885MRGPRX4 349/4885CYP3A4 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.